世界のデュシェンヌ型筋ジストロフィー市場予測 2020年-2025年

【英語タイトル】Global Duchenne Muscular Dystrophy Market Growth 2020-2025

LP Informationが出版した調査資料(LPI20AP8479)・商品コード:LPI20AP8479
・発行会社(調査会社):LP Information
・発行日:2020年3月25日(※2024年版があります。お問い合わせください)
・ページ数:139
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi UserUSD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate UserUSD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「デュシェンヌ型筋ジストロフィーの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、デフラザコート、プレドニゾン、その他など、用途別には、男性、女性などに区分してまとめた調査レポートです。デュシェンヌ型筋ジストロフィーのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・デュシェンヌ型筋ジストロフィーの世界市場概要(サマリー)
・デュシェンヌ型筋ジストロフィーの企業別販売量・売上
・デュシェンヌ型筋ジストロフィーの企業別市場シェア
・デュシェンヌ型筋ジストロフィーの世界市場規模 2015年-2020年:種類別(デフラザコート、プレドニゾン、その他)
・デュシェンヌ型筋ジストロフィーの世界市場規模 2015年-2020年:用途別(男性、女性)
・デュシェンヌ型筋ジストロフィーの米州市場規模(アメリカ、カナダ、メキシコなど)
・デュシェンヌ型筋ジストロフィーのアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・デュシェンヌ型筋ジストロフィーの欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・デュシェンヌ型筋ジストロフィーの中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・デュシェンヌ型筋ジストロフィー市場の成長要因・課題・動向
・デュシェンヌ型筋ジストロフィーの世界市場予測 2021年-2025年
・デュシェンヌ型筋ジストロフィーの米州市場予測(アメリカ、カナダ、メキシコなど)
・デュシェンヌ型筋ジストロフィーのアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・デュシェンヌ型筋ジストロフィーの欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・デュシェンヌ型筋ジストロフィーの中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・デュシェンヌ型筋ジストロフィーの世界市場予測:種類別(デフラザコート、プレドニゾン、その他)
・デュシェンヌ型筋ジストロフィーの世界市場予測:用途別(男性、女性)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Duchenne Muscular Dystrophy market will register a xx% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Duchenne Muscular Dystrophy business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy market by type, application, key manufacturers and key regions and countries.

This study considers the Duchenne Muscular Dystrophy value and volume generated from the sales of the following segments:

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Deflazacort
Prednisone
Others

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Male
Female

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
PTC Therapeutics
Sarepta Therapeutics
Others

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Duchenne Muscular Dystrophy consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Duchenne Muscular Dystrophy market by identifying its various subsegments.
Focuses on the key global Duchenne Muscular Dystrophy manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Duchenne Muscular Dystrophy with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Duchenne Muscular Dystrophy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Consumption 2015-2025
2.1.2 Duchenne Muscular Dystrophy Consumption CAGR by Region
2.2 Duchenne Muscular Dystrophy Segment by Type
2.2.1 Deflazacort
2.2.2 Prednisone
2.2.3 Others
2.3 Duchenne Muscular Dystrophy Consumption by Type
2.3.1 Global Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
2.3.2 Global Duchenne Muscular Dystrophy Revenue and Market Share by Type (2015-2020)
2.3.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2015-2020)
2.4 Duchenne Muscular Dystrophy Segment by Application
2.4.1 Male
2.4.2 Female
2.5 Duchenne Muscular Dystrophy Consumption by Application
2.5.1 Global Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
2.5.2 Global Duchenne Muscular Dystrophy Value and Market Share by Type (2015-2020)
2.5.3 Global Duchenne Muscular Dystrophy Sale Price by Type (2015-2020)

3 Global Duchenne Muscular Dystrophy by Company
3.1 Global Duchenne Muscular Dystrophy Sales Market Share by Company
3.1.1 Global Duchenne Muscular Dystrophy Sales by Company (2018-2020)
3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Company (2018-2020)
3.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company
3.2.1 Global Duchenne Muscular Dystrophy Revenue by Company (2018-2020)
3.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2018-2020)
3.3 Global Duchenne Muscular Dystrophy Sale Price by Company
3.4 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Duchenne Muscular Dystrophy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Duchenne Muscular Dystrophy by Regions
4.1 Duchenne Muscular Dystrophy by Regions
4.2 Americas Duchenne Muscular Dystrophy Consumption Growth
4.3 APAC Duchenne Muscular Dystrophy Consumption Growth
4.4 Europe Duchenne Muscular Dystrophy Consumption Growth
4.5 Middle East & Africa Duchenne Muscular Dystrophy Consumption Growth

5 Americas
5.1 Americas Duchenne Muscular Dystrophy Consumption by Countries
5.1.1 Americas Duchenne Muscular Dystrophy Consumption by Countries (2015-2020)
5.1.2 Americas Duchenne Muscular Dystrophy Value by Countries (2015-2020)
5.2 Americas Duchenne Muscular Dystrophy Consumption by Type
5.3 Americas Duchenne Muscular Dystrophy Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Duchenne Muscular Dystrophy Consumption by Regions
6.1.1 APAC Duchenne Muscular Dystrophy Consumption by Regions (2015-2020)
6.1.2 APAC Duchenne Muscular Dystrophy Value by Regions (2015-2020)
6.2 APAC Duchenne Muscular Dystrophy Consumption by Type
6.3 APAC Duchenne Muscular Dystrophy Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Duchenne Muscular Dystrophy by Countries
7.1.1 Europe Duchenne Muscular Dystrophy Consumption by Countries (2015-2020)
7.1.2 Europe Duchenne Muscular Dystrophy Value by Countries (2015-2020)
7.2 Europe Duchenne Muscular Dystrophy Consumption by Type
7.3 Europe Duchenne Muscular Dystrophy Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Duchenne Muscular Dystrophy by Countries
8.1.1 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Duchenne Muscular Dystrophy Value by Countries (2015-2020)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Type
8.3 Middle East & Africa Duchenne Muscular Dystrophy Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Duchenne Muscular Dystrophy Distributors
10.3 Duchenne Muscular Dystrophy Customer

11 Global Duchenne Muscular Dystrophy Market Forecast
11.1 Global Duchenne Muscular Dystrophy Consumption Forecast (2021-2025)
11.2 Global Duchenne Muscular Dystrophy Forecast by Regions
11.2.1 Global Duchenne Muscular Dystrophy Forecast by Regions (2021-2025)
11.2.2 Global Duchenne Muscular Dystrophy Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Duchenne Muscular Dystrophy Forecast by Type
11.8 Global Duchenne Muscular Dystrophy Forecast by Application

12 Key Players Analysis
12.1 PTC Therapeutics
12.1.1 Company Information
12.1.2 Duchenne Muscular Dystrophy Product Offered
12.1.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 PTC Therapeutics Latest Developments
12.2 Sarepta Therapeutics
12.2.1 Company Information
12.2.2 Duchenne Muscular Dystrophy Product Offered
12.2.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Sarepta Therapeutics Latest Developments
12.3 Others
12.3.1 Company Information
12.3.2 Duchenne Muscular Dystrophy Product Offered
12.3.3 Others Duchenne Muscular Dystrophy Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Others Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Research Methodology
Table 2. Data Source
Table 3. Duchenne Muscular Dystrophy Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Deflazacort
Table 5. Major Players of Prednisone
Table 6. Major Players of Others
Table 7. Global Consumption Sales by Type (2015-2020)
Table 8. Global Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Table 9. Global Duchenne Muscular Dystrophy Revenue by Type (2015-2020) ($ million)
Table 10. Global Duchenne Muscular Dystrophy Value Market Share by Type (2015-2020) ($ Millions)
Table 11. Global Duchenne Muscular Dystrophy Sale Price by Type (2015-2020)
Table 12. Global Consumption Sales by Application (2015-2020)
Table 13. Global Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Table 14. Global Duchenne Muscular Dystrophy Value by Application (2015-2020)
Table 15. Global Duchenne Muscular Dystrophy Value Market Share by Application (2015-2020)
Table 16. Global Duchenne Muscular Dystrophy Sale Price by Application (2015-2020)
Table 17. Global Duchenne Muscular Dystrophy Sales by Company (2017-2019) (K Doses)
Table 18. Global Duchenne Muscular Dystrophy Sales Market Share by Company (2017-2019)
Table 19. Global Duchenne Muscular Dystrophy Revenue by Company (2017-2019) ($ Millions)
Table 20. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2017-2019)
Table 21. Global Duchenne Muscular Dystrophy Sale Price by Company (2017-2019)
Table 22. Global Duchenne Muscular Dystrophy Manufacturing Base Distribution and Sales Area by Manufacturers
Table 23. Players Duchenne Muscular Dystrophy Products Offered
Table 24. Duchenne Muscular Dystrophy Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 25. Global Duchenne Muscular Dystrophy Consumption by Regions 2015-2020 (K Doses)
Table 26. Global Duchenne Muscular Dystrophy Consumption Market Share by Regions 2015-2020
Table 27. Global Duchenne Muscular Dystrophy Value by Regions 2015-2020 ($ Millions)
Table 28. Global Duchenne Muscular Dystrophy Value Market Share by Regions 2015-2020
Table 29. Americas Duchenne Muscular Dystrophy Consumption by Countries (2015-2020) (K Doses)
Table 30. Americas Duchenne Muscular Dystrophy Consumption Market Share by Countries (2015-2020)
Table 31. Americas Duchenne Muscular Dystrophy Value by Countries (2015-2020) ($ Millions)
Table 32. Americas Duchenne Muscular Dystrophy Value Market Share by Countries (2015-2020)
Table 33. Americas Duchenne Muscular Dystrophy Consumption by Type (2015-2020) (K Doses)
Table 34. Americas Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Table 35. Americas Duchenne Muscular Dystrophy Consumption by Application (2015-2020) (K Doses)
Table 36. Americas Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Table 37. APAC Duchenne Muscular Dystrophy Consumption by Countries (2015-2020) (K Doses)
Table 38. APAC Duchenne Muscular Dystrophy Consumption Market Share by Countries (2015-2020)
Table 39. APAC Duchenne Muscular Dystrophy Value by Regions (2015-2020) ($ Millions)
Table 40. APAC Duchenne Muscular Dystrophy Value Market Share by Regions (2015-2020)
Table 41. APAC Duchenne Muscular Dystrophy Consumption by Type (2015-2020) (K Doses)
Table 42. APAC Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Table 43. APAC Duchenne Muscular Dystrophy Consumption by Application (2015-2020) (K Doses)
Table 44. APAC Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Table 45. Europe Duchenne Muscular Dystrophy Consumption by Countries (2015-2020) (K Doses)
Table 46. Europe Duchenne Muscular Dystrophy Consumption Market Share by Countries (2015-2020)
Table 47. Europe Duchenne Muscular Dystrophy Value by Countries (2015-2020) ($ Millions)
Table 48. Europe Duchenne Muscular Dystrophy Value Market Share by Countries (2015-2020)
Table 49. Europe Duchenne Muscular Dystrophy Consumption by Type (2015-2020) (K Doses)
Table 50. Europe Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Table 51. Europe Duchenne Muscular Dystrophy Consumption by Application (2015-2020) (K Doses)
Table 52. Europe Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Table 53. Middle East & Africa Duchenne Muscular Dystrophy Consumption by Countries (2015-2020) (K Doses)
Table 54. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Countries (2015-2020)
Table 55. Middle East & Africa Duchenne Muscular Dystrophy Value by Countries (2015-2020) ($ Millions)
Table 56. Middle East & Africa Duchenne Muscular Dystrophy Value Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Duchenne Muscular Dystrophy Consumption by Type (2015-2020) (K Doses)
Table 58. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Table 59. Middle East & Africa Duchenne Muscular Dystrophy Consumption by Application (2015-2020) (K Doses)
Table 60. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Table 61. Duchenne Muscular Dystrophy Distributors List
Table 62. Duchenne Muscular Dystrophy Customer List
Table 63. Global Duchenne Muscular Dystrophy Consumption Forecast by Countries (2021-2025) (K Doses)
Table 64. Global Duchenne Muscular Dystrophy Consumption Market Forecast by Regions
Table 65. Global Duchenne Muscular Dystrophy Value Forecast by Countries (2021-2025) ($ Millions)
Table 66. Global Duchenne Muscular Dystrophy Value Market Share Forecast by Regions
Table 67. Global Duchenne Muscular Dystrophy Consumption Forecast by Type (2021-2025) (K Doses)
Table 68. Global Duchenne Muscular Dystrophy Consumption Market Share Forecast by Type (2021-2025)
Table 69. Global Duchenne Muscular Dystrophy Value Forecast by Type (2021-2025) ($ Millions)
Table 70. Global Duchenne Muscular Dystrophy Value Market Share Forecast by Type (2021-2025)
Table 71. Global Duchenne Muscular Dystrophy Consumption Forecast by Application (2021-2025) (K Doses)
Table 72. Global Duchenne Muscular Dystrophy Consumption Market Share Forecast by Application (2021-2025)
Table 73. Global Duchenne Muscular Dystrophy Value Forecast by Application (2021-2025) ($ Millions)
Table 74. Global Duchenne Muscular Dystrophy Value Market Share Forecast by Application (2021-2025)
Table 75. PTC Therapeutics Product Offered
Table 76. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 77. PTC Therapeutics Main Business
Table 78. PTC Therapeutics Latest Developments
Table 79. PTC Therapeutics Basic Information, Company Total Revenue (in $ million), Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 80. Sarepta Therapeutics Product Offered
Table 81. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 82. Sarepta Therapeutics Main Business
Table 83. Sarepta Therapeutics Latest Developments
Table 84. Sarepta Therapeutics Basic Information, Company Total Revenue (in $ million), Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
Table 85. Others Product Offered
Table 86. Others Duchenne Muscular Dystrophy Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 87. Others Main Business
Table 88. Others Latest Developments
Table 89. Others Basic Information, Company Total Revenue (in $ million), Duchenne Muscular Dystrophy Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Duchenne Muscular Dystrophy
Figure 2. Duchenne Muscular Dystrophy Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Duchenne Muscular Dystrophy Consumption Growth Rate 2015-2025 (K Doses)
Figure 5. Global Duchenne Muscular Dystrophy Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Deflazacort
Figure 7. Product Picture of Prednisone
Figure 8. Product Picture of Others
Figure 9. Global Duchenne Muscular Dystrophy Consumption Market Share by Type (2015-2020)
Figure 10. Global Duchenne Muscular Dystrophy Value Market Share by Type (2015-2020)
Figure 11. Duchenne Muscular Dystrophy Consumed in Male
Figure 12. Global Duchenne Muscular Dystrophy Market: Male (2015-2020) (K Doses)
Figure 13. Global Duchenne Muscular Dystrophy Market: Male (2015-2020) ($ Millions)
Figure 14. Duchenne Muscular Dystrophy Consumed in Female
Figure 15. Global Duchenne Muscular Dystrophy Market: Female (2015-2020) (K Doses)
Figure 16. Global Duchenne Muscular Dystrophy Market: Female (2015-2020) ($ Millions)
Figure 17. Global Duchenne Muscular Dystrophy Consumption Market Share by Application (2015-2020)
Figure 18. Global Duchenne Muscular Dystrophy Value Market Share by Application (2015-2020)
Figure 19. Global Duchenne Muscular Dystrophy Sales Market Share by Company in 2017
Figure 20. Global Duchenne Muscular Dystrophy Sales Market Share by Company in 2019
Figure 21. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2017
Figure 22. Global Duchenne Muscular Dystrophy Revenue Market Share by Company in 2019
Figure 23. Global Duchenne Muscular Dystrophy Sale Price by Company in 2019
Figure 24. Global Duchenne Muscular Dystrophy Consumption Market Share by Regions 2015-2020
Figure 25. Global Duchenne Muscular Dystrophy Value Market Share by Regions 2015-2020
Figure 26. Americas Duchenne Muscular Dystrophy Consumption 2015-2020 (K Doses)
Figure 27. Americas Duchenne Muscular Dystrophy Value 2015-2020 ($ Millions)
Figure 28. APAC Duchenne Muscular Dystrophy Consumption 2015-2020 (K Doses)
Figure 29. APAC Duchenne Muscular Dystrophy Value 2015-2020 ($ Millions)
Figure 30. Europe Duchenne Muscular Dystrophy Consumption 2015-2020 (K Doses)
Figure 31. Europe Duchenne Muscular Dystrophy Value 2015-2020 ($ Millions)
Figure 32. Middle East & Africa Duchenne Muscular Dystrophy Consumption 2015-2020 (K Doses)
Figure 33. Middle East & Africa Duchenne Muscular Dystrophy Value 2015-2020 ($ Millions)
Figure 34. Americas Duchenne Muscular Dystrophy Consumption Market Share by Countries in 2019
Figure 35. Americas Duchenne Muscular Dystrophy Value Market Share by Countries in 2019
Figure 36. Americas Duchenne Muscular Dystrophy Consumption Market Share by Type in 2019
Figure 37. Americas Duchenne Muscular Dystrophy Consumption Market Share by Application in 2019
Figure 38. United States Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 39. United States Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 40. Canada Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 41. Canada Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 42. Mexico Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 43. Mexico Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 44. APAC Duchenne Muscular Dystrophy Consumption Market Share by Countries in 2019
Figure 45. APAC Duchenne Muscular Dystrophy Value Market Share by Regions in 2019
Figure 46. APAC Duchenne Muscular Dystrophy Consumption Market Share by Type in 2019
Figure 47. APAC Duchenne Muscular Dystrophy Consumption Market Share by Application in 2019
Figure 48. China Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 49. China Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 50. Japan Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 51. Japan Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 52. Korea Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 53. Korea Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 54. Southeast Asia Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 55. Southeast Asia Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 56. India Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 57. India Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 58. Australia Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 59. Australia Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 60. Europe Duchenne Muscular Dystrophy Consumption Market Share by Countries in 2019
Figure 61. Europe Duchenne Muscular Dystrophy Value Market Share by Countries in 2019
Figure 62. Europe Duchenne Muscular Dystrophy Consumption Market Share by Type in 2019
Figure 63. Europe Duchenne Muscular Dystrophy Consumption Market Share by Application in 2019
Figure 64. Germany Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 65. Germany Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 66. France Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 67. France Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 68. UK Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 69. UK Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 70. Italy Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 71. Italy Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 72. Russia Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 73. Russia Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 74. Spain Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 75. Spain Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 76. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Countries in 2019
Figure 77. Middle East & Africa Duchenne Muscular Dystrophy Value Market Share by Countries in 2019
Figure 78. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Type in 2019
Figure 79. Middle East & Africa Duchenne Muscular Dystrophy Consumption Market Share by Application in 2019
Figure 80. Egypt Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 81. Egypt Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 82. South Africa Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 83. South Africa Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 84. Israel Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 85. Israel Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 86. Turkey Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 87. Turkey Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 88. GCC Countries Duchenne Muscular Dystrophy Consumption Growth 2015-2020 (K Doses)
Figure 89. GCC Countries Duchenne Muscular Dystrophy Value Growth 2015-2020 ($ Millions)
Figure 90. Global Duchenne Muscular Dystrophy Consumption Growth Rate Forecast (2021-2025) (K Doses)
Figure 91. Global Duchenne Muscular Dystrophy Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 92. Americas Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 93. Americas Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 94. APAC Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 95. APAC Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 96. Europe Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 97. Europe Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 98. Middle East & Africa Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 99. Middle East & Africa Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 100. United States Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 101. United States Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 102. Canada Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 103. Canada Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 104. Mexico Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 105. Mexico Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 106. Brazil Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 107. Brazil Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 108. China Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 109. China Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 110. Japan Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 111. Japan Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 112. Korea Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 113. Korea Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 114. Southeast Asia Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 115. Southeast Asia Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 116. India Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 117. India Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 118. Australia Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 119. Australia Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 120. Germany Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 121. Germany Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 122. France Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 123. France Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 124. UK Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 125. UK Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 126. Italy Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 127. Italy Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 128. Russia Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 129. Russia Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 130. Spain Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 131. Spain Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 132. Egypt Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 133. Egypt Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 134. South Africa Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 135. South Africa Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 136. Israel Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 137. Israel Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 138. Turkey Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 139. Turkey Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 140. GCC Countries Duchenne Muscular Dystrophy Consumption 2021-2025 (K Doses)
Figure 141. GCC Countries Duchenne Muscular Dystrophy Value 2021-2025 ($ Millions)
Figure 142. PTC Therapeutics Duchenne Muscular Dystrophy Market Share (2018-2020)
Figure 143. Sarepta Therapeutics Duchenne Muscular Dystrophy Market Share (2018-2020)
Figure 144. Others Duchenne Muscular Dystrophy Market Share (2018-2020)


★調査レポート[世界のデュシェンヌ型筋ジストロフィー市場予測 2020年-2025年] (コード:LPI20AP8479)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のデュシェンヌ型筋ジストロフィー市場予測 2020年-2025年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆